Our findings demonstrate targeted dephosphorylation of TFEB as an effective approach to target nuclear translocation of TFEB and it could be considered as an innovative therapeutic approach in pathologies, such as metabolic disorders, where enhanced TFEB-dependent transcription leading to increased lysosomal and mitochondrial biogenesis in metabolic tissues such as muscle and liver may be beneficial. This evidence concerns the gene TFEB and metabolic disease.